NEW YORK, Jan. 9 - Bruker AXS on Wednesday said that the underwriters of its initial public offering have exercised their over-allotment option and purchased an additional 1.35 million shares of common stock at $6.50 per share.
The action yields the X-ray systems developer roughly $8 million. The purchase also brings Bruker's IPO to 10.35 million shares with a market cap of approximately $62 million.
Bruker AXS last month earned $53 million after an IPO let loose 9 million shares of common stock at $6.50 apiece.
The two main underwriters were UBS Warburg and Thomas Weisel Partners. CIBC World Markets, SG Cowen, and Robert W. Baird & Co. were co-managers.
Bruker AXS develops and sells advanced systems for crystallography, X-ray diffraction, and X-ray fluorescence. It has development partnerships with GeneFormatics and an equity stake in Integrative Proteomics, and acquired the X-ray crystallography division of Delft Instruments in March.